Will HQY's Q1 2026 EPS beat forecasts like past quarters?

**HealthEquity's (HQY) Q1 2026 EPS is unlikely to beat forecasts** based on the following points: 1. **Recent Analyst Adjustments**: Zacks Research recently cut their Q1 2026 EPS estimates for HealthEquity from $0.95 to $0.68. This downward adjustment suggests that analysts are not expecting an EPS beat in the upcoming quarter. 2. **Consensus and Forecast Prices**: The average of current price targets set by analysts for HQY is $94, which is lower than the stock's last closing price of $78.8. This indicates a bearish sentiment among analysts, suggesting that they do not expect the stock to exceed its current price levels, let alone beat EPS forecasts. 3. **Historical Performance**: HealthEquity has shown volatility in its EPS performance. While the company's non-GAAP EPS of $0.80 for Q1 2024 beat expectations by $0.15, the GAAP EPS for the same quarter was not disclosed. Given the recent earnings estimate cuts, it is prudent to assume that the Q1 2026 EPS may not exceed forecasts unless there is a significant positive catalyst. In conclusion, based on the current analyst sentiment and recent adjustments to earnings estimates, it is more likely that HealthEquity's Q1 2026 EPS will fall short of forecasts rather than exceed them. Investors should remain cautious and monitor any updates from analysts or the company regarding earnings expectations.